Remove Cardiovascular Disease Remove Obesity Remove Preserved Ejection Fraction
article thumbnail

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

European Journal of Heart Failure

Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain.

Obesity 40
article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

Clinical and Investigative Horizons (Session 410) Sunday, April 7 4:30 – 5:45 p.m.

article thumbnail

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 4 Approximately 6.7

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52
article thumbnail

Highlights of ACC 2024

Cardiology Update

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52
article thumbnail

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovascular disease in women continues to be underrepresented and undertreated.

CME 103